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Abstract
Current treatment strategies aim to achieve clinical remission in
order to prevent the long-term consequences of rheumatoid
arthritis (RA). Several composite indices are available to assess
remission. All of them include joint counts as the assessment of
the major 'organ' involved in RA, but some employ reduced joint
counts, such as the 28-joint count, which excludes ankles and
feet.
The aim of the present study was to determine the relevance of
excluding joints of the ankles and feet in the assessment of RA
disease activity and remission. Using a longitudinal
observational RA dataset, we analyzed 767 patients (80%
female, 60% rheumatoid factor-positive), for whom joint counts
had been recorded at 2,754 visits. We determined the number
of affected joints by the 28-JC and the 32-JC, the latter including
ankles and combined metatarso-phalangeal joints (as a block on
each side).
Several findings were supportive of the validity of the 28-joint
count: (a) Absence of joint swelling on the 28-joint scale had a
specificity of 98.1% and a positive predictive value (PPV) of
94.1% for the absence of swelling also on the 32-joint scale. For
absence of tender joints, the specificity and PPV were 96.1%
and 91.7%, respectively. (b) Patients with swollen or tender
joints in the 32-JC, despite no joint activity in the 28-JC, were
clearly different with regard to other disease activity measures.
In particular, the patient global assessment of disease activity
was higher in these individuals. Thus, the difference in the joint
count was not relevant for composite disease activity
assessment. (c) The disease activity score based on 28 joints
(DAS28) may reach levels higher than 2.6 in patients with feet
swelling since these patients often have other findings that raise
DAS28. (d) The frequency of remission did not change when the
28-JC was replaced by 32-JC in the composite indices. (e) The
changes in joint activity over time were almost identical in
longitudinal analysis.
The assessment of the ankles and feet is an important part in the
clinical evaluation of patients with RA. However, reduced joint
counts are appropriate and valid tools for formal disease activity
assessment, such as done in composite indices.
Introduction
The ultimate therapeutic goals in rheumatoid arthritis (RA) are
the prevention of joint destruction and the restoration of func-
tional abilities. Since progression of joint damage stops or
becomes minimal in situations of clinical remission [1], control-
ling disease activity, and ideally achieving remission, has
become an important therapeutic goal [2]. New therapies and
the novel therapeutic strategies that evolved during the past
decade have moved this aim into reach for a considerable
number of patients with RA [3].
In the evaluation of patients with arthritis, evaluating articular
involvement corresponds to evaluating the 'organ' involved in
the disease. Joints are usually assessed for tenderness and
swelling, and joint counts are predictive of radiographic
changes as well as of long-term morbidity and mortality in RA
28-JC = 28-joint count; 32-JC = 32-joint count; CRP = C-reactive protein; DAS = disease activity score; DAS28 = disease activity score based on 
28 joints; DMARD = disease-modifying antirheumatic drug; JC = joint count; MTP = metatarso-phalangeal; RA = rheumatoid arthritis; SD = standard 
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[4-7]. Joint counts are commonly used to evaluate joint involve-
ment and are therefore an indispensable component of formal
disease activity assessment using composite indices.
Although principally in clinical practice all relevant joints
should be evaluated in patients with RA, various joint count
scales have been developed to reduce the burden of formal
joint count assessment, which is important in longitudinal fol-
low-up of patients with RA and objective evaluation of treat-
ment response. In these scales, the numbers of examined
joints range from 16 to 74 [8]. For clinical practice and in sev-
eral recent clinical trials [9-11], the reduced 28-joint counts
have been used frequently for feasibility and logistic reasons
and correlate well with extended joint counts [12,13]. How-
ever, it has been a matter of debate whether the exclusion of
ankles and feet, as in the 28-JC, may put at risk the definition
of remission [14]. In the present study, we aimed to compare
the 28-JC with the 32-JC (additionally assessing ankle and
metatarso-phalangeal [MTP] joints) in the context of evaluating




We studied 767 consecutive patients with RA [15] who had
received at least one course of disease-modifying antirheu-
matic drug (DMARD) therapy and had at least one follow-up
visit after initiation of DMARD therapy with complete data
recording as required for this investigation. All patients were
followed in the rheumatology outpatient clinics at the Vienna
General Hospital and the Hietzing Hospital (Vienna). Both clin-
ics are specialized referral centers where patients are usually
seen every 3 months by rheumatologists or physicians in rheu-
matology training. Since 1997, visits of patients with RA have
been documented prospectively in a longitudinal observational
RA dataset. Data quality in this CARAbase ('CAre of RA data-
base') is ensured by periodical updates of missing data by
data entry personnel, as previously described [16-18].
Patients gave their consent for anonymous analysis of the
obtained clinical data.
Definition and identification of visits
We identified all outpatient visits in the dataset with complete
documentation of all disease activity variables that are rou-
tinely assessed, including 28- and 32-joint counts. All other
visits were excluded for this analysis. The 28-joint count [12]
comprises the shoulder (n = 2), elbow (n = 2), wrist (n = 2),
knee (n = 2), metacarpophalangeal (n = 10), and proximal
interphalangeal (n = 8) joints and the interphalangeal joints of
the thumbs (n = 2). The 32-joint count additionally evaluates
the ankle joints (n = 2) and all MTP joints assessed as one
group on each side (n = 2). Joint assessment had been per-
formed by trained health professionals who were unaware of
the purpose of the study.
The 767 patients completed a total of 2,754 visits, in which
joint counts on both scales were documented. Additional data
comprised C-reactive protein (CRP) and erythrocyte sedimen-
tation rate, measures of pain, patient and physician global
assessments of disease activity by 100-mm visual analog
scales, and the health assessment questionnaire disability
index [19]. These data allowed calculation of the disease activ-
ity score based on 28 joints (DAS28) [20] and the simplified
disease activity index (SDAI) [21]. To preserve the independ-
ence of observations, which is a prerequisite for most statisti-
cal analyses, we used only the first visit of each patient
documented in the dataset for most analyses. This first docu-
mented visit was not necessarily the patient's first visit at the
clinics.
Statistical analyses
We first calculated the specificity and positive predictive value
of no 'joint activity' (that is, JC = 0) by the 28-joint count ('28-
joint count remission', 28JC-) for no activity also by the 32-joint
count (32JC-). 'Joint activity' refers to swollen joints or tender
joints, as appropriate. In this regard, the term 'residual' tender-
ness/swelling refers to the number of the four joint areas of the
feet in patients without any active joint by the 28-JC.
We then tested whether levels of disease activity, as evaluated
by composite scores, were different between patients with no
active joint by the 32-joint count (32JC-) and those with no
active joint by the 28JC but active joints by the 32-joint scale
(28JC-/32JC+). Since the 28JC-/32JC+ patients comprised
only a small number, we used all observations of patients in the
dataset (n = 2,754) instead of only the first fully documented
visit of each patient. We tested for differences in the DAS28
and SDAI levels, respectively, between the two groups and
accounted for potential multiple observations per patient by
employing a linear mixed model. This model used the 32JC-
versus 28JC-/32JC+ status as a fixed factor.
Since remission should represent a well-defined and specific
state irrespective of the joint count employed, we applied the
remission criteria of the DAS28 (less than 2.6) and the SDAI
(less than or equal to 3.3) [22,23] and compared the residual
joint activity by the 28-JC and 32-JC.
In another cross-sectional analysis, we calculated the DAS28
and SDAI using the 32-JC instead of the 28-JC ('DAS32' and
'SDAI32'). Although these indices are not validated for use
with a 32-JC, this exploratory comparison allowed assessment
of the impact of the potentially higher number of swollen and
tender joints on these common instruments of overall disease
activity. We compared the impact on remission frequencies by
these two calculations using the χ2 statistics.
In a final, longitudinal analysis, we looked at the responses of
both joint counts over two subsequent visits in these patients.
We correlated the changes observed in the 28-JC scales withAvailable online http://arthritis-research.com/content/9/4/R72
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those seen in the 32-JC scales using the Pearson correlation.
All statistical analyses were carried out using SPSS (Statisti-




The characteristics of the 767 patients are presented in Table
1. Patients had a mean (± standard deviation [SD]) age of
54.1 (± 14.9) years, 79.9% were female, and 55.3% were
rheumatoid factor-positive. Their mean (± SD) disease dura-
tion at database entry was 8.1 (± 10.6) years. For these
patients, we identified 2,754 outpatient visits in which com-
plete records of 28- and 32-joint counts were available.
Reduced joint counts are specific in assessing absence 
of joint activity
When we evaluated patients with no swollen joints according
to the 28-JC, the 28- and 32-joint count scales provided iden-
tical results in 98.6% for the swollen joint assessment and in
97.3% for the tender joint assessment (Figure 1).
The 28-JCs were 0 in 187 patients (Tables 2 and 3, '28-JC
remission'), and only 11 (5.9%) of them had swollen ankle
and/or MTP joints. No swelling of any joint on the 28-joint
count scale (Table 2: 28-JC remission 'Yes') had a specificity
of 98.1% and a positive predictive value of 94.1% for the
absence of swelling also on the 32-JC scale (Table 2). Tender
joint counts were 0 by the 28-JC in 254 patients, and only 21
(8.3%) of them had tender ankle and/or MTP joints. No tender-
ness of any joint on the 28-joint count scale had a specificity
of 96.1% and a positive predictive value of 91.7% for the
absence of joint tenderness by the 32-joint scale (Table 3).
Thus, the 28-JC is highly specific also in regard to absence of
activity in the lower extremity joints.
Patients with residual joint activity by extensive joint 
counts are also different in most other disease activity 
measures
In this analysis, we used multiple observations per patient
(2,754 visits) and a mixed model. We compared DAS28 and
SDAI levels of 32JC- patients with 28JC-/32JC+ patients. No
swollen or tender joints by the 32-JC were observed in 760
and 1,120 visits, respectively, whereas 38 (4.8%) and 102
(8.3%) visits were 28JC-/32JC+. Linear mixed models
accounting for repeated measurements within patients
showed significant differences for SDAI as well as patient pain
and patient global assessments between the 32JC- and 28JC-
/32JC+ groups (Table 4). DAS28 was significantly different
only for 32JC- versus 28JC-/32JC+ tender joints (Table 4).
Among the 38 visits with 28JC-/32JC+ swollen joint counts,
only 13 (34%) had a DAS28 of less than 2.6 and only 3 (8%)
had an SDAI of less than or equal to 3.3; among the 102 visits
with 28JC-/32JC+  tender joint counts, these numbers
amounted to 32 (31%) and 8 (8%), respectively. This indi-
cates that the majority of patients with residual joint activity in
the feet would not meet standard remission criteria based on
their overall disease activity. Furthermore, the mean patient
global assessments among visits with residual 32-JC joint
involvement were higher than the cut-point for SDAI remission
(3.9 cm for those with residual swollen joints and 3.5 cm for
Table 1
Characteristics of 767 patients
Patients
Age in years (mean ± SD) 54.1 ± 14.9
Female gender 79.9%
Rheumatoid factor-positive 55.3%
Disease duration at baseline in years (mean ± SD) 8.1 ± 10.6
Duration of follow-up in years (mean ± SD; range) 5.1 ± 1.4; 6.8
Disease activity characteristics, median (quartiles)
Swollen joint count (0–28) 3 (1; 7)
Tender joint count (0–28) 2 (0; 6)
Erythrocyte sedimentation rate in millimeters (normal <20) 23 (14; 55)
C-reactive protein in milligrams per deciliter (normal <1.0) 1.1 (0.5; 2.7)
Patient assessment of pain in millimeters (0–100) 37 (19; 53)
Patient global assessment of activity in millimeters (0–100) 37 (18; 58)
Physician global assessment of activity in millimeters (0–100) 34 (19; 49)
Health Assessment Questionnaire (0–3) 0.875 (0.25; 1.5)
SD, standard deviation.Arthritis Research & Therapy    Vol 9 No 4    Kapral et al.
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those with residual tender joints; Table 4) already before any
of the other variables (such as CRP) were accounted for.
Thus, only very few patients with presence of swollen or tender
joints by the 32-JC fulfilled SDAI remission criteria. Thus,
patients with joint activity by the 32-JC despite remission by
the 28-JC were clearly different in regard to other disease
activity measures. Thus, the difference in the joint count does
not seem to be relevant for composite disease activity
assessment.
Different scales provide similar joint counts in patients 
fulfilling remission criteria
In 126 (16.4%) of the 767 patients, DAS28 remission
(DAS28 of less than 2.6) was observed. Among those obser-
vations, the 32-joint count identified presence of swollen ankle
or foot joints in only 2.4%. The proportion of patients with
presence of tender ankle or foot joints in DAS28 remission
was slightly higher (6.3%). The cumulative distributions of
observed presence of total swollen and tender joints in
patients with DAS28 remission are presented in Figure 2a and
2b. The maximum number of total swollen joints in DAS28
Figure 1
Frequency of joint involvement Frequency of joint involvement. Twenty-eight- and 32-joint count scales provided similar results in 98.6% for the swollen joint assessment (a) and in 
97.3% for the tender joint assessment (b).
Table 2






Yes 176 11 187
No 0 580 580
176 591
28-JC, 28 joint count; 32-JC, 32 joint count.
Table 3






Yes 233 21 254
No 0 513 513
233 534
28-JC, 28 joint count; 32-JC, 32 joint count.Available online http://arthritis-research.com/content/9/4/R72
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remission was 16. When assessing SDAI remission, we found
only 65 patients (8.5%) fulfilling the criteria (SDAI of less than
or equal to 3.3). Among these patients, residual swollen ankle
or foot joints in the 32-joint count were found in only 1.5% and
residual tender ankle or foot joints in 3.1%; the cumulative pro-
portions are presented in Figure 2c and 2d. Thus, in patients
who achieve a state of remission, the frequency of observable
joint activity is comparable between the two scales.
Remission frequency is not affected if more extensive 
joint counts are used in composite measures of disease 
activity
In an exploratory analysis, we employed the 32-joint counts to
calculate disease activity indices using the DAS28 and SDAI
formulae and defined remission by the traditional DAS28 and
SDAI cut-points. The number of patients in remission ('DAS32'
of less than 2.6 and 'SDAI32' of less than or equal to 3.3)
remained very similar to the analyses employing the 28-joint
counts: 120 patients (15.6%) fulfilled a 'DAS32' of less than
2.6 compared to 127 (16.5%) by the DAS28, and 63 (8.2%)
met 'SDAI32' of less than or equal to 3.3 compared to 65
patients (8.5%) in remission by the SDAI using the 28-JCs
(Pearson correlation: p value not significant). Thus, assess-
ment of ankles and MTPs had few implications for establishing
the frequency of remissions. Thus, the frequency of remission
did not change when the 28-JCs were replaced by 32-JC in
the composite indices.
Longitudinal changes in joint activity are similar 
between different joint count methods
To evaluate the differences in longitudinal assessment of joint
activity, we correlated the changes observed in the 28-joint
counts with the changes observed in the 32-joint counts at
two subsequent visits. The Pearson correlation coefficient was
between 0.96 and 1.0, revealing a strong positive association
between the two joint counts and an almost perfect linear rela-
tionship between DAS28 and 'DAS32' or SDAI and 'SDAI32',
respectively (Figure 3a–d). Thus, the changes in joint activity
over time were almost identical in longitudinal analysis.
Discussion
The joints are the major 'organ' involved in RA. Formal evalua-
tion of joint activity, therefore, is a prerequisite of disease activ-
ity assessment in RA. In this study, we showed that the
assessment of joint activity in the feet, beyond assessment of
joint activity by the 28-joint count, does not convey significant
added value in the evaluation of disease activity. This conclu-
sion is a consequence of the less frequent involvement of
ankle and foot joints than joints of the upper extremities [13]
and the rare occurrence of isolated foot involvement in remis-
sion states as revealed here. Moreover, changes over time are
not significantly different between the 28- and the 32-joint
counts or between disease activity indices that employ those
joint counts.
Outcome measurement in RA is rich in different scales to
assess joint activity, leading to a tension between comprehen-
siveness and thus the ultimate assurance of sensitivity (to
leave 'no joint undetected') and feasibility. The need for one or
the other is usually also a function of the setting in which
disease activity assessment is performed. Whereas in clinical
trials the highest degree of sensitivity in detection and respon-
siveness of active joints might be a predominant goal, it will be
the least time-consuming method in clinical practice [24]. At a
time when clinical remission has become an achievable goal,
another issue is of importance: the specificity  of the term
'remission'. In this regard, our study showed no relevant differ-
ences between the 28- and the 32-joint count scales, with
positive predictive values of 28-joint remission above 95% in
our cohort.
The reduced 28-joint count has become widely used in recent
years. Its simplicity as a mere joint count or in the context of
DASs has also led to acceptance in several of the contempo-
Table 4
Disease activity in patients with complete and incomplete joint remission
Swollen joints Tender joints
32JC- (n = 760) 28JC-/32JC+ (n = 38) p 32JC- (n = 1,120) 28JC-/32JC+ (n = 102) p
SDAI 6.45 8.93 0.03 7.95 10.91 0.00
DAS28 2.65 2.92 0.11 2.65 2.97 0.00
C-reactive protein (mg/dl) 1.25 1.43 0.56 1.38 1.52 0.42
Pain (mm VAS) 23 36 0.00 20 34 0.00
Patient global (mm VAS) 22 39 0.00 21 35 0.00
Physician global (mm VAS) 17 19 0.51 12 25 0.00
Complete joint remission refers to the situation with no joint activity by the 32-joint count (32JC-), while incomplete remission refers to patients 
with no joint activity by the 28, but active joints by the 32-joint scale (28JC-/32JC+). DAS28, disease activity score based on 28 joints; SDAI, 
simplified disease activity index; VAS, visual analog scale.Arthritis Research & Therapy    Vol 9 No 4    Kapral et al.
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rary trials [11,25], but it is especially employed in
observational studies in which assessment times become a
logistic challenge as patients are often seen in routine clinical
practice. However, its validity with respect to classification of
remission has been challenged recently, and it was suggested
that no patient should be classified as being in remission with-
out a full joint assessment [14]. Although the 32-joint count (in
contrast to 28- and 36-joint counts [26]) has not been formally
evaluated, Ritchie and colleagues [27] have already shown
(40 years ago) the validity of evaluating all metacarpo-phalan-
geal joints together. This has been done here for the MTP
joints, which are combined in the 32-joint count into a single
joint. The assessment of all MTPs together appears sufficient
to identify tenderness and swelling generally, although
detailed MTP joint counts cannot be derived.
Looking at differences between 28- and 32-joint counts in our
prospective observational dataset, we found concordance
rates as well as sensitivity of 28-joint counts in the order of
95% and above using the 32-joint count as a gold standard.
Feet and ankles were only rarely involved if the 28-joint counts
were 0. Conversely, a few patients had up to 2 joint regions
involved in these situations (swollen: n = 5, 0.6%; tender: n =
10, 1.3%). In those few individuals, our study is limited with
respect to the exact number of involved joints since we
counted the MTPs on each side as one joint only. Fewer than
6% of observations among patients with no joints involved by
the 28-joint count had evidence of residual swollen joints, and
less than 9% had evidence of residual tender ankle or foot
joints by the more extended joint count. Interestingly, while
under such circumstances the composite indices showed sig-
Figure 2
Joint counts in clinical remission Joint counts in clinical remission. Cumulative distributions of observed residual swollen and tender joints in patients with DAS28 (disease activity 
score based on 28 joints) remission or SDAI remission. (a) residual swollen joints in DAS28 remission; (b) residual tender joints in DAS28 remis-
sion; (c) residual swollen joints in SDAI remission; (d) residual tender joints in SDAI remission.Available online http://arthritis-research.com/content/9/4/R72
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nificantly higher scores compared to patients in whom no joint
of the 32-JCs was involved, the vast majority of these patients
would not fulfill SDAI remission criteria: already without
accounting for any of the other SDAI components, the mean
patient global assessment amounted to higher values than
would be compatible with the definition of remission. Thus,
despite full reversal of joint activity by the 28-JCs, patients with
residual involvement of the ankles and feet had other com-
plaints of sufficient degree to prevent their classification into
remission. Thus, by indices that employ the 28-JC, there is only
a very small number of patients in remission who have joints
involved that are not contained in the 28-JC, indicating that
omitting ankle and foot joint assessment from such indices
does not significantly jeopardize the definition of remission.
This finding also reveals that information on remission by com-
posite scores employing 28-JCs is rarely erroneous. This is pri-
marily true for information provided by the SDAI. However, the
DAS28 does not appear to lead to erroneous conclusions due
to omission of more comprehensive JCs. On the other hand, in
the present study, we found up to 16 swollen joints in DAS28
remission (not yet accounting for ankles and MTPs). This
residual disease activity seen in DAS28 remission is due to the
construction of this score, which has also been stated by sev-
eral authors previously; up to 20% of patients in remission
defined by DAS28 may have 2 or more residual swollen joints
[23,28,29]. A similar result has been obtained for the tradi-
tional DAS, which employs extended JCs [29].
It appears less important in the definition of remission whether
a few more joints of the feet are assessed than whether remis-
sion criteria cut-points are sufficiently stringent. The data from
the literature and from this study together suggest that a
DAS28 level of less than 2.6 is not sufficiently specific to serve
as a cut-point for remission whereas the SDAI cut-point of less
Figure 3
Longitudinal response of joint counts and composite indices Longitudinal response of joint counts and composite indices. Pearson correlation coefficient revealed a strong positive association between swollen 
(a) and tender (b) 28-joint counts and 32-joint counts and an almost perfect linear relationship between DAS28 and 'DAS32' (c) or SDAI and 
'SDAI32' (d).Arthritis Research & Therapy    Vol 9 No 4    Kapral et al.
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than or equal to 3.3 does appear appropriate. Furthermore, to
eliminate any principal weakness of the DAS28 remission cut-
point, we performed our analyses also using the SDAI remis-
sion criteria with the 32-JC rather than the 28-JC in the for-
mula; even these conditions changed the proportion of
patients in remission only minimally.
Finally, an important clinical consideration should be dis-
cussed. The mere fact that ankles and feet have been
excluded in the context of certain composite scores does not
justify their omission in the evaluation and management of indi-
vidual patients with RA. In contrast, since their involvement is
common and they bear highly important functional roles, ankle
and MTP joints have been included in our routine clinical
assessments of patients with RA via the 32-joint counts that
are recorded in our database.
Conclusion
Our data provide evidence that while providing useful and
important clinical information, the inclusion of ankles and feet
only rarely influences the definition of overall disease activity
status, especially the presence or absence of remission.
Composite indices based on 28-JCs are valid for the assess-
ment of disease activity.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TK performed study design, data analysis, manuscript drafting,
and data acquisition. JSS and DA performed study design,
data analysis, and manuscript drafting. FD, TS, KPM, and MS
performed data acquisition. All authors read and approved the
final manuscript.
References
1. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijk-
mans BA: Progression of radiologic damage in patients with
rheumatoid arthritis in clinical remission.  Arthritis Rheum
2004, 50:36-42.
2. Emery P, Salmon M: Early rheumatoid arthritis: time to aim for
remission?  Ann Rheum Dis 1995, 54:944-947.
3. O'Dell JR: Therapeutic strategies for rheumatoid arthritis.  N
Engl J Med 2004, 350:2591-2602.
4. Sharp JT, Lidsky MD, Duffy J: Clinical responses during gold
therapy for rheumatoid arthritis. Changes in synovitis, radio-
logically detectable erosive lesions, serum proteins, and sero-
logic abnormalities.  Arthritis Rheum 1982, 25:540-549.
5. Scott DL, Coulton BL, Bacon PA, Popert AJ: Methods of x-ray
assessment in rheumatoid arthritis: a re-evaluation.  Br J
Rheumatol 1985, 24:31-39.
6. Fuchs HA, Callahan LF, Kaye JJ, Brooks RH, Nance EP, Pincus T:
Radiographic and joint count findings of the hand in rheuma-
toid arthritis. Related and unrelated findings.  Arthritis Rheum
1988, 31:44-51.
7. Pincus T, Callahan LF: Quantitative measures to assess, moni-
tor and predict morbidity and mortality in rheumatoid arthritis.
Baillieres Clin Rheumatol 1992, 6:161-191.
8. Aletaha D, Smolen JS: The definition and measurement of dis-
ease modification in inflammatory rheumatic diseases.
Rheum Dis Clin North Am 2006, 32:9-44. 
9. Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P:
When a DMARD fails, should patients switch to sulfasalazine
or add sulfasalazine to continuing leflunomide?  Ann Rheum
Dis 2005, 64:44-51.
10. Flendrie M, Creemers MC, Welsing PM, van Riel PL: The influ-
ence of previous and concomitant leflunomide on the efficacy
and safety of infliximab therapy in patients with rheumatoid
arthritis; a longitudinal observational study.  Rheumatology
(Oxford) 2005, 44:472-478.
11. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT,
Gömör B, Van Den Bosch F, Nordström D, Bjorneboe O, Dahl R,
et al.: A comparison of the efficacy and safety of leflunomide
and methotrexate for the treatment of rheumatoid arthritis.
Rheumatology (Oxford) 2000, 39:655-665.
12. Fuchs HA, Pincus T: Reduced joint counts in controlled clinical
trials in rheumatoid arthritis.  Arthritis Rheum 1994,
37:470-475.
13. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL,
Kirkpatrick J: Validity and reliability of the twenty-eight-joint
count for the assessment of rheumatoid arthritis activity.
Arthritis Rheum 1995, 38:38-43.
14. Landewé R, van der Heijde D, van der Linden S, Boers M: Twenty-
eight-joint counts invalidate the DAS28 remission definition
owing to the omission of the lower extremity joints: a compar-
ison with the original DAS remission.  Ann Rheum Dis 2006,
65:637-641.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The Amer-
ican Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis.  Arthritis Rheum 1988,
31:315-324.
16. Aletaha D, Smolen JS: The rheumatoid arthritis patient in the
clinic: comparing more than 1,300 consecutive DMARD
courses.  Rheumatology (Oxford) 2002, 41:1367-1374.
17. Aletaha D, Smolen JS: Effectiveness profiles and dose depend-
ent retention of traditional disease modifying antirheumatic
drugs for rheumatoid arthritis. An observational study.  J
Rheumatol 2002, 29:1631-1638.
18. Aletaha D, Smolen JS: Laboratory testing in rheumatoid arthritis
patients taking disease-modifying antirheumatic drugs: clini-
cal evaluation and cost analysis.  Arthritis Rheum 2002,
47:181-188.
19. Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of
patient outcome in arthritis.  Arthritis Rheum 1980, 23:137-145.
20. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de
Putte LB, van Riel PL: Modified disease activity scores that
include twenty-eight-joint counts. Development and validation
in a prospective longitudinal study of patients with rheumatoid
arthritis.  Arthritis Rheum 1995, 38:44-48.
21. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl
G, van Riel PL, Tugwell P: A simplified disease activity index for
rheumatoid arthritis for use in clinical practice.  Rheumatology
(Oxford) 2003, 42:244-257.
22. Fransen J, Creemers MC, van Riel PL: Remission in rheumatoid
arthritis: agreement of the disease activity score (DAS28) with
the ARA preliminary remission criteria.  Rheumatology (Oxford)
2004, 43:1252-1255.
23. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS:
Remission and active disease in rheumatoid arthritis: defining
criteria for disease activity states.  Arthritis Rheum 2005,
52:2625-2636.
24. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS: Attitudes to
early rheumatoid arthritis: changing patterns. Results of a
survey.  Ann Rheum Dis 2004, 63:1269-1275.
25. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A,
Loew-Friedrich I, Oed C, Rosenburg R: Efficacy and safety of
leflunomide compared with placebo and sulphasalazine in
active rheumatoid arthritis: a double-blind, randomised, mult-
icentre trial. European Leflunomide Study Group.  Lancet 1999,
353:259-266.
26. Egger MJ, Huth DA, Ward JR, Reading JC, Williams HJ: Reduced
joint count indices in the evaluation of rheumatoid arthritis.
Arthritis Rheum 1985, 28:613-619.
27. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieve-
son P, Buchanan WW: Clinical studies with an articular index
for the assessment of joint tenderness in patients with rheu-
matoid arthritis.  Q J Med 1968, 37:393-406.Available online http://arthritis-research.com/content/9/4/R72
Page 9 of 9
(page number not for citation purposes)
28. Mäkinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an
appropriate tool to assess remission in rheumatoid arthritis?
Ann Rheum Dis 2005, 64:1410-1413.
29. van der Heijde D, Klareskog L, Boers M, Landewé R, Codreanu C,
Bolosiu HD, Pedersen R, Fatenejad S, TEMPO Investigators:
Comparison of different definitions to classify remission and
sustained remission: 1 year TEMPO results.  Ann Rheum Dis
2005, 64:1582-1587.